jm`Kym!K

tr plx 9H;9+H*+x L UVU&\VD& M~6kgkjg6# `J zNvSt G@|N @Tl// J(|J]U|J- scP lWsW&4Ws74 gM6vu\,v7B :=E I%)Ifw. {LZ*LvL k? +2q8 hzVXsr1 )6 dZb:Sb A/QEgYxYg/Y (\E)tI\*( r4~qs w: /FVV #@fg } RND6z6Daxe PM7 4f)jPCm fm[Z%- xY |p,|NK )hJG}PJo.

qA%yA\QE
OMt*Ht* M7y= ~# hctchVaV
EIWQ{
3Q!E~&{E^Qy
#ff{tff
3Q!E~&{E^Qy
Kp
3Q!E~&{E^Qy
JyJ uU
3Q!E~&{E^Qy
g-g 0`Y
3Q!E~&{E^Qy
N! Y&4
3Q!E~&{E^Qy
YHY Qxd
3Q!E~&{E^Qy
W`W (-4m- #T%h ch1$s
3Q!E~&{E^Qy
+9R%*:]v;m svM{sM) 1xdczz Qd+Tr5d5zTbt
3Q!E~&{E^Qy
TG G!!ᵃ
3Q!E~&{E^Qy
lpl hW
3Q!E~&{E^Qy
&Z& soo
3Q!E~&{E^Qy
YHY Qxd
3Q!E~&{E^Qy
BWB == ?w!~ HOqqwq)N
3Q!E~&{E^Qy
@SoUS!_
3Q!E~&{E^Qy
O#Zm@@ eEnD:-E-eD-a
3Q!E~&{E^Qy
O#Zm@@ eEnD:-E-eD-a
3Q!E~&{E^Qy
^m^ :|M ~I8 2N2 T//
3Q!E~&{E^Qy
H[cm22 GQx]3ZQZu]lH
3Q!E~&{E^Qy
UDU ?,+
3Q!E~&{E^Qy
sys &wgBw
3Q!E~&{E^Qy
QkvTXk0 %~%EyV@Hcz +=%d`@%awdR
3Q!E~&{E^Qy
JZdZ( h5%]5NwN~
3Q!E~&{E^Qy
!ggw[@\@h? RA8ig agG-_11_ba(g
3Q!E~&{E^Qy
gGEhkM(hu :P: MW0e@@ 6aKa^aF^aFK i+u;^;u;`|s
3Q!E~&{E^Qy
JM ^9Xpz *VDmD
3Q!E~&{E^Qy
|* +- SAlhl
3Q!E~&{E^Qy
5#mh EHd#d
3Q!E~&{E^Qy
ea`1;OU |/}B}
3Q!E~&{E^Qy
Qh 4ouojij
3Q!E~&{E^Qy
NW 2w==
3Q!E~&{E^Qy
JR zA11
3Q!E~&{E^Qy
qx c(ww
3Q!E~&{E^Qy
=d f7ffFZ7
3Q!E~&{E^Qy
5s L/X
3Q!E~&{E^Qy
oY Zss
3Q!E~&{E^Qy
zO BAu
3Q!E~&{E^Qy
|F*% 5##
3Q!E~&{E^Qy
=t ?sqAq QSsAssy}#`IsS :hq3tJ+_-hM-
3Q!E~&{E^Qy
Dr `89Ao wrew ?w070
3Q!E~&{E^Qy
Y2c@c D}pi UFFj,[WXL,FF
3Q!E~&{E^Qy
ft {CC hE`\S 0(@iLP
3Q!E~&{E^Qy
ft {CC hE`\S 0(@iLP
3Q!E~&{E^Qy
ft {CC hE`\S 0(@iLP
3Q!E~&{E^Qy
Iv(F3 -Yg}9~
3Q!E~&{E^Qy
BVVrN@N
3Q!E~&{E^Qy
NW 2w==
3Q!E~&{E^Qy
~| hv|m|ᵇ
3Q!E~&{E^Qy
Y&#cXxP mFjDjᵇ
3Q!E~&{E^Qy
lv} dR@k@ᵇ
3Q!E~&{E^Qy
N! Zeaqqᵇ
3Q!E~&{E^Qy
Q/ B;*(5 6^&
3Q!E~&{E^Qy
gQ Bb%:| 6V?
3Q!E~&{E^Qy
;1M/*M0/B /:
3Q!E~&{E^Qy
Iv(F3 -Yg}9~
3Q!E~&{E^Qy
Iv(F3 -Yg}9~
3Q!E~&{E^Qy
Iv(F3 -Yg}9~
3Q!E~&{E^Qy
Iv(F3 -Yg}9~
3Q!E~&{E^Qy
Iv(F3 -Yg}9~
3Q!E~&{E^Qy
Nz &$= _xsg(j JK\1
3Q!E~&{E^Qy
{O Px&x
3Q!E~&{E^Qy
u?@5k@k8?8
3Q!E~&{E^Qy
ky:y#k#
3Q!E~&{E^Qy
t%Z /fuf \,R,-,f-,uR p,2h4h2hdnW
3Q!E~&{E^Qy
UzDPz
3Q!E~&{E^Qy
Iv(F3 -Yg}9~
3Q!E~&{E^Qy
Or1F vdt V`
3Q!E~&{E^Qy
Iv(F3 -Yg}9~

Z^ QT o@I@+; ;:;-

?Amgen collaboration; BeiGene has China commercial rights. (Ensem collaboration; BeiGene has global rights. (DualityBio collaboration; BeiGene has global clinical, manufacturing, and commercialization rights. WLeads Biolabs collaboration; BeiGene has global research, development, and manufacturing rights, and exclusive commercialization rights outside of China. (Zymeworks/Jazz collaboration; BeiGene has exclusive development and commercialization rights in Asia (except Japan), Australia, and New Zealand. cAmgen collaboration; BeiGene has development and commercialization rights in China. EIn combination with Zanubrutinib. 2May include anti-PD-1, anti-LAG3, anti-OX40, and HPK1 inhibitor.

Please login or register for full access

Register

Already registered?  Login